Business
Delcath Systems Reports Second Quarter 2024 Results and Business Highlights
Company Reports $7.8 million in Quarterly Revenue Conference Call Today at 4:30pm Eastern Time QUEENSBURY, N.Y.--(BUSINESS WIRE)-- Delcath Systems, Inc.
About this update from Delcath Systems, Inc.
[{"type":"text","content":"\nCompany Reports $7.8 million in Quarterly Revenue\n\n\nConference Call Today at 4:30pm Eastern Time\n\n\n QUEENSBURY, N.Y.--(BUSINESS WIRE)--\nDelcath Systems, Inc. (Nasdaq: DCTH) (“Delcath” or the “Company”), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today reported financial results and business highlights for the second quarter ended June 30, 2024.\n\n\nRecent Business Highlights\n\n\n\nRecognized second quarter 2024 revenues of $6.6 million from sales of HEPZATO KIT™ (melphalan/Hepatic Delivery System) and $1.2 million in CHEMOSAT sales;\n\n\n\n\nActivated three HEPZATO KIT treating centers in the US during the second quarter with an additional center in July for a total of eight active treating centers. Two additional centers have completed the necessary steps and have scheduled their first treatments in August. An additional four centers are ready to conduct their first commercial treatment and are currently in the process of scheduling patients for treatment;\n\n\n\n\nReceived New Technology Add-on Payment status (NTAP) on August 1, 2024 for HEPZATO from the Centers for Medicare & Medicaid Services (CMS) which provides hospitals additional payments to cover the costs associated with the treatment for cases in the inpatient setting. While HEPZATO KIT is used primarily in the outpatient setting, there are instances where it is used in the inpatient setting;\n\n\n\n\nPublished key results from the pivotal Phase 3 FOCUS study of HEPZATO KIT in patients with unresectable metastatic Uveal Melanoma in the journal Annals of Surgical Oncology;\n\n\n\n\nAnnounced the acceptance of the FOCUS study efficacy analysis as a poster presentation at the upcoming ESMO conference to be held September 2024;\n\n\n\n\nReported that independent investigators at the Leiden University have enrolled 70 of the total 76 patients planned in the Phase 2 part of the CHOPIN trial which is evaluating the effect of sequencing Immunotherapy with CHEMOSAT liver directed therapy;\n\n\n\n\nExecuted an amendment with Synerx Pharma, LLC and Mylan Teoranta for Delcath’s supply of melphalan hydrochloride which extends the term of the original agreement to December 31, 2028;\n\n\n\n\nAppointed Dr. Bridget Martell to the Company’s Board of Directors effective May 23, 2024;\n\n\n\n\nSubmitted the fina...